1 - 10 of 44 articles
Key PointsQuestionIs osimertinib, a third-generation tyrosine kinase inhibitor (TKI), a cost-effective first-line therapy for treatment-naive, epidermal growth factor receptor gene (EGFR)-mutated, non–small cell lung cancer?
FindingsIn this cost-effectiveness analysis of data from the FLAURA...
This Viewpoint describes the increasing imbalance in health care costs and health coverage in oncology and suggests a strategy to develop a comprehensive cost of care task force.
A woman in her 30s with metastatic soft tissue sarcoma being treated with nivolumab presented with diffuse macular cutaneous eruption and pruritus. What is your diagnosis?
Key PointsQuestionHow does a climate of expanding targeted and immune therapies but declining funding from the National Institutes of Health affect the conduct of radiotherapy trials compared with other oncological trials?
FindingsIn a cross-sectional analysis of 25 907 interventional...
Key PointsQuestionIs there an association between hormone replacement therapy (HRT) use after oophorectomy and risk of breast cancer among women with a BRCA1 mutation.
FindingsResults of this prospective study suggest no association between ever use of any type of HRT after oophorectomy compared...
Read and print from thousands of top scholarly journals.
Continue with Facebook
Sign up with Google
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.